A769662 Inhibits Insulin-Stimulated Akt Activation in Human Macrovascular Endothelial Cells Independent of AMP-Activated Protein Kinase
Open Access
- 5 December 2018
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (12) , 3886
Abstract
Protein kinase B (Akt) is a key enzyme in the insulin signalling cascade, required for insulin-stimulated NO production in endothelial cells (ECs). Previous studies have suggested that AMP-activated protein kinase (AMPK) activation stimulates NO synthesis and enhances insulin-stimulated Akt activation, yet these studies have largely used indirect activators of AMPK. The effects of the allosteric AMPK activator A769662 on insulin signalling and endothelial function was therefore examined in cultured human macrovascular ECs. Surprisingly, A769662 inhibited insulin-stimulated NO synthesis and Akt phosphorylation in human ECs from umbilical veins (HUVECs) and aorta (HAECs). In contrast, the AMPK activators compound 991 and AICAR had no substantial inhibitory effect on insulin-stimulated Akt phosphorylation in ECs. Inhibition of AMPK with SBI-0206965 had no effect on the inhibition of insulin-stimulated Akt phosphorylation by A769662, suggesting the inhibitory action of A769662 is AMPK-independent. A769662 decreased IGF1-stimulated Akt phosphorylation yet had no effect on VEGF-stimulated Akt signalling in HUVECs, suggesting that A769662 attenuates early insulin/IGF1 signalling. The effects of A769662 on insulin-stimulated Akt phosphorylation were specific to human ECs, as no effect was observed in the human cancer cell lines HepG2 or HeLa, as well as in mouse embryonic fibroblasts (MEFs). A769662 inhibited insulin-stimulated Erk1/2 phosphorylation in HAECs and MEFs, an effect that was independent of AMPK in MEFs. Therefore, despite being a potent AMPK activator, A769662 has effects unlikely to be mediated by AMPK in human macrovascular ECs that reduce insulin sensitivity and eNOS activation.Keywords
Funding Information
- British Heart Foundation (FS/14/61/31284, PG/13/82/30483)
- Diabetes UK (BDA11/0004309)
This publication has 65 references indexed in Scilit:
- Elevated NF-κB Activation Is Conserved in Human Myocytes Cultured From Obese Type 2 Diabetic Patients and Attenuated by AMP-Activated Protein KinaseDiabetes, 2011
- AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant MiceCell Metabolism, 2011
- The role of AMP-activated protein kinase in the functional effects of vascular endothelial growth factor-A and -B in human aortic endothelial cellsVascular Cell, 2011
- Activation of AMPK stimulates heme oxygenase-1 gene expression and human endothelial cell survivalAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK ActivationCell Metabolism, 2010
- Activation of AMP-activated Protein Kinase by Vascular Endothelial Growth Factor Mediates Endothelial Angiogenesis Independently of Nitric-oxide SynthaseJournal of Biological Chemistry, 2010
- Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implicationsReviews in Endocrine and Metabolic Disorders, 2010
- Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterationsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein KinaseJournal of Biological Chemistry, 2007
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006